CAMBRIDGE, Mass. — Decoy Therapeutics has expanded its intellectual property portfolio covering its Designable Multi-Antivirals and IMP³ACT drug-design platform.
The biotechnology company said its portfolio now includes seven patent families and 19 pending applications across the United States, Australia, Canada, China, Europe, Japan and New Zealand.
The patents and applications cover antiviral peptide conjugates, manufacturing methods, formulations and the computational platform used to design the therapies. Decoy said it solely owns all of the intellectual property.
“Our IP position has grown alongside the science,” said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. “The early filings protected our first conjugates. The newer families protect the engineered sequences our platform now designs, the methods we use to make them, and the platform itself.”
Decoy has received U.S. Patent No. 12,226,474, titled “Methods and Compositions for Treating Infections.” The patent covers antiviral peptide conjugates containing one or more viral spike protein sequences that include D-amino acids.
Another patent family covers automated flow peptide synthesis methods and linker technologies used to manufacture Decoy’s antiviral peptide conjugates. The company said this is its most broadly filed patent family, with applications pending in six jurisdictions outside the United States.
Additional applications cover engineered antiviral compounds designed to target conserved features of class I viral fusion proteins. These filings extend beyond naturally occurring peptide sequences and include formulations and methods intended to interrupt viral transmission.
The applications cover potential therapies targeting paramyxoviruses, including measles, mumps, human parainfluenza virus and Nipah virus.
Decoy’s newest patent application, filed in June, covers the design methods used by its IMP³ACT platform to create new class I fusion peptides and related therapeutics. The application has not yet been published.
Decoy is developing Designable Multi-Antivirals, known as D-MAVs, as potential treatments for multiple viral infections.
